newsfilter
← Latest News
Business Wire·

Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer's Disease

Alpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce